US FDA’s Tidmarsh: Marginal Treatments Do More Harm Than Good

 
• By Sarah Karlin-Smith
  
Large Red arrow curving upward with a businessman pushing it up.
Industry must raise their standards for new drug candidates, US FDA's CDER director said. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership